Sales expanded sharply in the September quarter. The difficulty is that costs absorbed the increase, leaving investors with an uncomfortable question about the new earnings base.

There is no shortage of growth in Zydus Lifesciences’ September-quarter numbers. Consolidated revenue reached ₹7,909.6 crore in Q2 FY27, a 29.2% increase over last year. Yet profit attributable to shareholders dropped 26.6% to ₹925.5 crore. EBITDA was ₹1,894.5 crore, roughly 6% lower. When turnover rises by almost a third and operating earnings move backwards, the cost of generating that demand becomes a key factor.

The company is expanding beyond its established formulations portfolio, with speciality medicine, wellness and newer businesses playing a larger role. That broadening may prove valuable. For now, the income statement shows an awkward transition: Zydus is selling more, while retaining less of each rupee of sales.

The Quarter In Numbers

Pharma Revenue up 22%; Wellness up 76%

Pharmaceutical revenue increased 22% to approximately ₹6,407.5 crore. North American formulations, an important source of cash generation for the group, advanced 21%. Consumer wellness grew much faster—76%, to roughly ₹1,122.3 crore—but that figure includes an acquisition. 

These are very different businesses. Conventional formulations, differentiated medicines and consumer products do not command identical margins or require the same commercial spending. The shift in revenue mix is one reason the group margin deserves closer scrutiny. Investors need a clearer sense of where the incremental sales originated and how much each business contributed to operating profit.

EBITDA Margin Falls ~9 Percentage Points

EBITDA margin slipped to 24.0% from 32.9%. That is an unusually large change in one year. Total expenditure climbed to around ₹6,807 crore from ₹4,509 crore. Employee expenses rose from about ₹1,034 crore to ₹1,357 crore, while other expenses increased from ₹1,797 crore to nearly ₹2,640 crore. The larger organisation has become considerably more expensive to operate.

It is tempting to describe the rise as investment for future growth, and some of it probably is. New-product launches, a wider commercial network and scientific work all require spending well before the revenue contribution becomes visible. Still, not every additional rupee is a one-off. Staff costs and spending associated with an enlarged business tend to remain in the base. A recovery in profitability needs evidence of better sales productivity..

There was more pressure below operating profit. Depreciation and amortisation approached ₹604.5 crore, against ₹300.3 crore a year earlier. Finance costs increased to roughly ₹187 crore from ₹101 crore. Depreciation is not an immediate cash outflow, but it reflects capital already committed. Higher finance costs are a more direct drag on earnings, and both these figures help explain why the fall in PAT was steeper than the decline in EBITDA.

Research Spending Is Not An Ordinary Overhead

Research and development amounted to approximately ₹657.3 crore, or 8.3% of revenue. It would be simplistic to argue that Zydus should cut this spending just to improve one quarter’s margin. The company is pursuing differentiated products, biologics and speciality opportunities that could eventually reduce its reliance on competitive generics. Those programmes have their own development and regulatory timelines.

An approved and commercially successful treatment could support better pricing and a more durable profit stream. Projects delayed in trials or regulatory review may consume years of expenditure without a comparable payoff. The pipeline gives Zydus strategic options; it does not yet justify assuming that today’s research bill will automatically turn into future earnings.

A Wider Portfolio Also Makes the Accounts Harder to Read

Sterling Biotech’s API business was acquired on 2 November 2026, after the quarter closed. Its purchase therefore does not explain the Q2 numbers. It will, however, make the next few results more complicated to compare, particularly around capital employed, financing and integration costs. 

The same caution applies to newer operating segments. A business can add revenue and strategic capability while temporarily reducing the group’s reported margin. That is not inherently a bad trade, provided management can demonstrate a credible route to satisfactory returns. At present, the gap between group sales growth and earnings growth makes those segment economics more important than ever.

The Valuation Question Is About the Sustainable Margin

The shares traded around ₹1,262 on 4 November 2026, putting the equity value close to ₹1.26 lakh crore. A market snapshot before the latest result showed a trailing multiple of roughly 28 times earnings but a lower profit base changes the denominator.

Zydus has businesses that deserve attention: an established North American presence, a broader international franchise and opportunities in differentiated medicines. But a larger portfolio does not by itself make the company more valuable. A higher multiple is harder to defend when the benefit of growth is being offset by costs, depreciation and interest.

The next result will be revealing for a few specific reasons. Can formulations growth continue without a similar rise in commercial expenses? How much of wellness growth is organic? Does operating margin recover from 24%, and does operating cash flow keep pace with profit? Answers to those questions would help distinguish a costly but temporary transition from a lasting reduction in the group’s earnings power.

The September quarter did not show a company short of customers. It showed a company whose expansion has outrun its profit conversion. That is a very different problem—and, for shareholders, the more consequential one.